RxDoctor Payments DataLook up a doctor →

Abdallah Dlewati, MD

Endocrinology, Diabetes & Metabolism · Flint, MINPI 1609054899

Payments from drug & device makers

$9,418in general payments, 2019–2025

Across 521 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$780
  • Lilly USA, LLC$731
  • Abbott$721
  • Amgen$542
  • Corcept Therapeutics$452
  • Sanofi-aventis U.S. LLC$450
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,406100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk44$780
Lilly USA, LLC39$731
Abbott67$721
Amgen(2 entities)29$542
Corcept Therapeutics23$452
Sanofi-aventis U.S. LLC22$450
Boehringer Ingelheim18$353
Radius Health, Inc.15$298
AbbVie16$298
Antares Pharma, Inc.11$283
Xeris Pharmaceuticals, Inc.15$281
AstraZeneca(2 entities)17$278
Merck14$276
Medtronic(2 entities)16$254
Amarin Pharma, Inc.13$219
Amneal Pharmaceuticals LLC10$197
Bayer9$192
Lifescan, Inc.9$177
Halozyme Inc4$165
Dexcom, Inc.8$156
Esperion Therapeutics, Inc.9$152
Insulet Corporation6$138
Ipsen Biopharmaceuticals, Inc6$134
Astellas Pharma US Inc6$113
IBSA Pharma Inc.6$103
Alvogen Inc5$100
Pfizer6$96
Recordati_rare_diseases_inc.4$84
BD4$80
Mannkind Corporation4$75
Evoke Pharma, Inc.4$75
Verity Pharmaceuticals Inc.3$69
Amphastar Pharmaceuticals, Inc.3$68
BETA Bionics, Inc.3$65
Ascendis Pharma Endocrinology Inc3$62
Johnson & Johnson3$58
Amryt Pharma Holdings Ltd3$52
Cequr Corporation3$47
Ascensia Diabetes Care US Inc.2$47
Embecta Corp.2$47
Clarus Therapeutics Inc.2$46
Currax Pharmaceuticals LLC3$44
Sequel Med Tech, LLC2$43
Zealand Pharma US, Inc.2$43
Kyowa Kirin, Inc.2$39
Neurocrine Biosciences, Inc.2$37
Nevro Corp.1$36
Acerus Pharmaceuticals Corporation2$35
Ferring Pharmaceuticals Inc.2$35
Acella Pharmaceuticals, LLC2$33
Tolmar, Inc.2$32
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$30
Companion Medical, Inc.2$28
Gilead1$27
Kowa Pharmaceuticals America, Inc.2$23
Madrigal Pharmaceuticals1$23
Ultragenyx Pharmaceutical Inc.1$18
Azurity Pharmaceuticals, Inc.1$17
Nalpropion Pharmaceuticals LLC1$15
Shire North American Group Inc1$14

How this compares

$9,418 in reported general payments places this provider in the 70th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan

Medicare billing

Part B allowed, 2024
$232,644
Medicare patients
776
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide472$863,012
JardianceEmpagliflozin390$538,560
MounjaroTirzepatide137$273,614
FarxigaDapagliflozin Propanediol129$168,549
Tresiba Flextouch U-100Insulin Degludec130$116,760
TrulicityDulaglutide53$108,124
JanuviaSitagliptin Phosphate83$95,769
Tresiba Flextouch U-200Insulin Degludec43$83,488
Novolog FlexpenInsulin Aspart194$75,259
Lantus SolostarInsulin Glargine,hum.Rec.Anlog355$71,574
TradjentaLinagliptin44$53,235
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$44,106
Humalog Kwikpen U-100Insulin Lispro102$38,524
TymlosAbaloparatide11$34,452
RybelsusSemaglutide19$29,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$780$910,417529 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr$353$598,269445 claims
Lilly USA, LLCMounjaro, Trulicity$731$381,738190 claims
AstraZenecaFarxiga$278$168,549129 claims
MerckJanuvia$276$95,76983 claims
Radius Health, Inc.Tymlos$298$34,45211 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$197$10,896915 claims
AbbVieSynthroid$298$10,06192 claims
Sanofi-aventis U.S. LLCLantus$450$4,67518 claims
PfizerLevoxyl$96$1,61072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →